Key Risks Identified by the FDA

The U.S. Food and Drug Administration (FDA) has warned consumers not to purchase or use Qu Feng Huo Lou Dan, a product marketed as a pain reliever, following laboratory analysis that detected dexamethasone, a corticosteroid not listed on the label. The product was distributed through the New Green USA website, multiple online channels, and some retail outlets. Unlike drugs that go through Phase 1, 2, 3 trials or are formally approved, this product is not a clinically tested pharmaceutical but rather a supplement marketed for pain relief. The core issue of this action is not about efficacy but about the quality and labeling violations that expose consumers to an unregulated prescription steroid with unknown dosing.

Clinical Implications of Undisclosed Dexamethasone

Dexamethasone (brand name Decadron) is a synthetic corticosteroid that targets the glucocorticoid receptor to suppress inflammation and immune responses. It was first FDA-approved on October 30, 1958, and is used as an adjunct in the short-term management of acute flare-ups in rheumatic diseases. However, this product does not provide information on dosage or administration. The FDA has warned of risks including immunosuppression, hyperglycemia, muscle damage, and mental health disturbances. Prescribing information also highlights risks of hypothalamic-pituitary-adrenal axis suppression and Cushing’s syndrome. Consumers who have been exposed for extended periods and discontinue use abruptly may experience corticosteroid withdrawal and adrenal insufficiency, requiring medical supervision for safe discontinuation.

Competitive Landscape with Standard Therapies

Standard management for joint pain and osteoarthritis includes exercise, weight management, and topical nonsteroidal anti-inflammatory drugs (NSAIDs) such as Voltaren Arthritis Pain (diclofenac sodium). Oral NSAIDs or intra-articular corticosteroids may be used if needed. Diclofenac inhibits cyclooxygenase (COX-1 and COX-2) and is a marketed therapeutic with clear labeling on dosage, contraindications, and gastrointestinal and cardiovascular risks, in contrast to Qu Feng Huo Lou Dan, which lacks regulatory oversight. The American College of Rheumatology guidelines recommend topical and oral NSAIDs and intra-articular glucocorticoids for knee osteoarthritis but do not include undisclosed oral steroid products as treatment options. Therefore, this warning does not question the efficacy of dexamethasone itself but aims to prevent uncontrolled exposure from products that conceal approved ingredients.

Market and Regulatory Implications

The global joint health supplement market was valued at USD 17.14 billion in 2025 and is projected to grow to USD 18.60 billion in 2026 and USD 32.92 billion by 2033, making online quality control a critical factor in industry valuation. The FDA warning is not a recall or new drug approval decision but a regulatory action urging consumers to discontinue use and report adverse events via MedWatch. It does not involve separate pharmaceutical deals or upfront, milestone, royalty, or equity terms. In the short term, sales channels like New Green USA face product removal, audit burdens for payment and advertising partners, and increased regulatory compliance. In the medium to long term, businesses with robust ingredient testing, manufacturing records, and adverse event systems, as well as FDA-approved therapeutics, are expected to gain a valuation premium.